ATE338819T1 - Antigenes protein aus malassezia - Google Patents

Antigenes protein aus malassezia

Info

Publication number
ATE338819T1
ATE338819T1 AT96941211T AT96941211T ATE338819T1 AT E338819 T1 ATE338819 T1 AT E338819T1 AT 96941211 T AT96941211 T AT 96941211T AT 96941211 T AT96941211 T AT 96941211T AT E338819 T1 ATE338819 T1 AT E338819T1
Authority
AT
Austria
Prior art keywords
antigenic protein
malassezia
fragments
antigenic
protein
Prior art date
Application number
AT96941211T
Other languages
English (en)
Inventor
Kazutoh Takesako
Takashi Okado
Tomoko Yagihara
Masanobu Kuroda
Yoshimi Onishi
Ikunoshin Kato
Kazuo Akiyama
Hiroshi Yasueda
Hideyo Yamaguchi
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8257612A external-priority patent/JPH09221498A/ja
Priority claimed from JP8257613A external-priority patent/JPH1077296A/ja
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of ATE338819T1 publication Critical patent/ATE338819T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96941211T 1995-12-12 1996-12-10 Antigenes protein aus malassezia ATE338819T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34662795 1995-12-12
JP8257612A JPH09221498A (ja) 1995-12-12 1996-09-05 マラセチア由来の抗原性蛋白質
JP8257613A JPH1077296A (ja) 1996-09-05 1996-09-05 組換えマラセチア抗原性蛋白質並びにその遺伝子

Publications (1)

Publication Number Publication Date
ATE338819T1 true ATE338819T1 (de) 2006-09-15

Family

ID=27334643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941211T ATE338819T1 (de) 1995-12-12 1996-12-10 Antigenes protein aus malassezia

Country Status (10)

Country Link
US (3) US6432407B1 (de)
EP (2) EP1792992A1 (de)
JP (1) JP3990730B2 (de)
KR (1) KR100465382B1 (de)
AT (1) ATE338819T1 (de)
AU (1) AU717150B2 (de)
CA (1) CA2238278C (de)
DE (1) DE69636527D1 (de)
TW (1) TW565567B (de)
WO (1) WO1997021817A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990730B2 (ja) * 1995-12-12 2007-10-17 タカラバイオ株式会社 マラセチア由来の抗原性蛋白質
DE69738525T2 (de) * 1996-09-04 2009-02-19 Takara Bio Inc., Otsu Pilz-antigene und verfahren zu deren herstellung
CN1140801C (zh) * 2000-03-01 2004-03-03 胡军 检测血液中淋巴细胞对特定抗原反应性的方法
PT103510B (pt) * 2006-06-27 2009-07-21 Inst Nac De Saude Dr Ricardo J Utilização da fasciolina (fh8) e/ou de seus derivados na detecção de hospedeiros infectados por fasciola hepática por intradermoreacção
AU2008316225B2 (en) * 2007-10-26 2014-06-19 Avivagen Inc. Compositions and methods for enhancing immune response
US9295816B2 (en) * 2009-12-09 2016-03-29 Osprey Medical, Inc. Catheter with distal and proximal ports
JP6232618B2 (ja) * 2012-06-28 2017-11-22 国立大学法人広島大学 ヒト汗中に含まれる新規ヒスタミン遊離物質
JP6385005B2 (ja) * 2012-08-17 2018-09-05 国立大学法人広島大学 汗アレルギー抗原蛋白質に結合するモノクローナルＩｇＥ抗体
WO2020079120A1 (en) 2018-10-18 2020-04-23 Basf Se Process for producing ammonium (meth-) acrylate
WO2021204850A1 (en) 2020-04-09 2021-10-14 Basf Se Biocatalytic synthesis of monomer mixtures for polyacrylamide manufacturing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990730B2 (ja) * 1995-12-12 2007-10-17 タカラバイオ株式会社 マラセチア由来の抗原性蛋白質

Also Published As

Publication number Publication date
DE69636527D1 (de) 2006-10-19
KR19990071959A (ko) 1999-09-27
KR100465382B1 (ko) 2005-04-14
US7491405B2 (en) 2009-02-17
US6432407B1 (en) 2002-08-13
EP0955366B1 (de) 2006-09-06
CA2238278C (en) 2009-03-03
EP0955366A1 (de) 1999-11-10
AU717150B2 (en) 2000-03-16
JP3990730B2 (ja) 2007-10-17
EP0955366A4 (de) 2002-08-14
US20030105283A1 (en) 2003-06-05
AU1041397A (en) 1997-07-03
WO1997021817A1 (fr) 1997-06-19
EP1792992A1 (de) 2007-06-06
US6911208B2 (en) 2005-06-28
CA2238278A1 (en) 1997-06-19
TW565567B (en) 2003-12-11
US20080069829A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
NO20100061L (no) Forhindring og behandling av amyloidogen sykdom
DE60125797D1 (de) Impfstoffzusammesetzung
TR199801722T2 (xx) Peptit imm�nojenler.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
BG101118A (en) Therapeutical compounds
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
CA2246715A1 (en) Antibody variants
NO20012716D0 (no) Terapeutisk middel for undertrykkelse av snorkelyder
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
HUP0105490A2 (hu) Az IgE C-epszilon-3 vagy C-epszilon-4 doménjéből származtatott epitópok és mimotópok, antagonistáik és terápiás alkalmazásuk
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE338819T1 (de) Antigenes protein aus malassezia
AU2967595A (en) Anti-protozoan methods and materials
DK1032391T3 (da) Sfæroider indeholdende tiagabin, fremstillingsproces og farmaceutisk sammensætning
WO2003004049A3 (en) Use of polyclonal anti-hiv goat serum as a therapeutic agent
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
IE871769L (en) Fluorooxirane carboxylates
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties